ILMN vs. ROIV: Illumina vs. Roivant Sciences Stock Comparison

Company Profile

Illumina (ILMN) and Roivant Sciences (ROIV) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but ILMN is classified in Life Sciences Tools & Services while ROIV is classified in Biotechnology.

Illumina (ILMN) has more than two decades of public-market history since July 28, 2000, whereas Roivant Sciences (ROIV) listed on December 8, 2020 and has a much shorter record to draw on.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Roivant Sciences (ROIV) reports a negative ROE of -8.52%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Illumina (ILMN) reports 32.39%, ranking against industry peers normally.

Illumina (ILMN) at 19.72% converts revenue to bottom-line profit above its industry’s benchmark range, while Roivant Sciences (ROIV) at 0.00% keeps roughly the typical share for its industry.

Roivant Sciences (ROIV) reports a negative operating margin of -25,408.11%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Illumina (ILMN) reports 20.02%, ranking against industry peers normally.

Profitability Metrics

Growth

Both Illumina (ILMN) at -0.66% and Roivant Sciences (ROIV) at -71.57% post bottom-quartile revenue growth versus peers, pointing to weaker demand or pricing momentum than typical rivals.

Neither Illumina (ILMN) nor Roivant Sciences (ROIV) reports a EPS growth value for this period, so a direct comparison isn't possible.

Growth Metrics

Financial Strength

Illumina (ILMN) at 2.63 keeps current ratio within its industry’s typical mid-range, while Roivant Sciences (ROIV) at 16.72 sits above its industry’s typical mid-range — comfortable liquidity, though possibly with more idle current assets relative to peers.

Roivant Sciences (ROIV) at 0.02 carries an industry-typical debt-to-equity mix, while Illumina (ILMN) at 0.74 uses more debt funding than most peers.

Financial Strength Metrics

Dividends

Neither Illumina (ILMN) nor Roivant Sciences (ROIV) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither Illumina (ILMN) nor Roivant Sciences (ROIV) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: Illumina (ILMN) trades at 36.68 times trailing earnings, ranked against its peers, while Roivant Sciences (ROIV) has no P/E ratio this period.

Illumina (ILMN) at 7.10 prices around its industry’s typical P/S ratio, while Roivant Sciences (ROIV) at 3,728.61 clears its benchmark range — ROIV looks notably rich on sales.

Both Illumina (ILMN) at 10.30 and Roivant Sciences (ROIV) at 6.64 carry a premium to book value versus peers, sitting in the upper P/B ratio quartile of their industries.

Valuation Metrics